Auto

6 November 2025

## **ZF Commercial Vehicles**

ANANDRATHI

Near-term macro headwinds; growth rear-ended with ADAS; retaining a Buy

Above ARe's Rs1.03bn, ZF's Q2 EBITDA fell 5% y/y to Rs1.32bn due to more -than-expected revenue and gross margin. We expect 12/10/13% revenue/ EBITDA/PAT growth over FY25-28 driven by 1) ADAS regulation draft notification, proposing ESC, AEBS and four ADAS functions with content opportunity of >Rs65,000/vehicle for M&H CVs (>9-tonne trucks/buses); 2) ESC regulation implemented for most bus segments from Sep'25; 3) Content would increase on higher tonnage mix, EV penetration and new products (particularly for LCVs); 4) The company's dominant market share would continue across M&H CVs even for coming opportunities; 5) India's M&H CV sector to record a healthy 5% CAGR over FY25-28, led by infra/economic activity and GST reforms; 6) Overseas CVs may be muted in the near term (from ongoing trade wars), but export revenue would outstrip that of the industry due to more sourcing by global group companies. We retain a Buy at a slightly higher TP of Rs15,900, 50x Sep'27e P/E (earlier 15,700, 50x Sep'27e P/E).

**EBITDA** above estimate. O2 standalone revenue fell 1% v/v to Rs9.02bn, above our estimate (Rs8.54bn) due to better-than-expected domestic OEM and exports. Product sales fell 2% to Rs7.2bn (OEM up 7%, exports down 16%, aftermarket up 13%), and services grew 9% to Rs1.24bn. Export products declined 16% y/y mainly due to a ~20% decline in the US due to tariffs, partially offset by growth in Europe (up 9%)/ EMEA. EBITDA fell 5% to Rs1.32bn, above our Rs1.03bn estimate, due to higher-than-expected revenue and gross margin. The EBITDA margin contracted 70bps v/v to 14.6% (but q/q up 140bps). The gross margin expanded 160bps q/q to 43.7%. Overall, PAT fell 3% y/y to Rs1.06bn, above ARe's Rs821m due to higher operating income. The subsidiary's (Oragadam plant) revenue/EBITDA/PAT were Rs114m/23m/18m.

Valuation. We expect 12/13% revenue/PAT CAGRs over FY25-28. Our FY26e-28e EPS is slightly more due to higher other income, despite lower revenue and operating margins estimates. We retain a Buy with a slightly higher TP of Rs15,900, 50x Sep'27e P/E. **Key risks:** Less-than-expected growth in underlying segments; delay in new regulations for CVs; adverse commodities/forex; trade wars.

FY24	FY25	FY26e	FY27e	FY28e
37,837	38,041	38,477	42,841	53,947
4,048	4,587	4,499	5,394	6,674
213.4	241.8	237.2	284.4	351.9
60.0	52.9	54.0	45.0	36.4
40.8	36.4	39.8	32.9	26.4
8.7	7.6	6.7	5.9	5.1
11.7	11.5	9.9	10.4	11.3
16.0	15.5	13.4	14.1	15.3
0.1	0.1	0.1	0.2	0.2
-0.5	-0.5	-0.5	-0.5	-0.5
	37,837 4,048 213.4 60.0 40.8 8.7 11.7 16.0	37,837 38,041 4,048 4,587 213.4 241.8 60.0 52.9 40.8 36.4 8.7 7.6 11.7 11.5 16.0 15.5 0.1 0.1	37,837     38,041     38,477       4,048     4,587     4,499       213.4     241.8     237.2       60.0     52.9     54.0       40.8     36.4     39.8       8.7     7.6     6.7       11.7     11.5     9.9       16.0     15.5     13.4       0.1     0.1     0.1	37,837         38,041         38,477         42,841           4,048         4,587         4,499         5,394           213.4         241.8         237.2         284.4           60.0         52.9         54.0         45.0           40.8         36.4         39.8         32.9           8.7         7.6         6.7         5.9           11.7         11.5         9.9         10.4           16.0         15.5         13.4         14.1           0.1         0.1         0.1         0.2

Rating: **Buy** Target price (12-mnth): Rs.15,900 Share price: Rs.12,802

Key data	ZCVCS IN / WIL.BO
52-week high / low	Rs15284 / 9567
Sensex / Nifty	83311 / 25510
Market cap	Rs244bn
Shares outstanding	19m

Shareholding pattern (%)	Sep'25	Jun'25	Mar'25
Promoters	60.0	60.0	63.2
- of which, Pledged	-	-	-
Free float	40.0	40.0	36.8
- Foreign institutions	5.8	5.7	5.6
- Domestic institutions	26.3	26.4	23.3
- Public	8.0	7.9	7.9

Estimates revision (%)	FY26e	FY27e	FY28e
Sales	-2.2	-3.4	0.1
EBITDA	-8.5	-5.7	-3.1
EPS	3.1	0.1	2.7



Source: Bloomberg

Mumuksh Mandlesha Research Analyst

> Shagun Beria Research Associate

**Dishant Jain** Research Associate

Anand Rathi Share and Stock Brokers Limited (hereinafter "ARSSBL") is a full-service brokerage and equities-research firm and the views expressed therein are solely of ARSSBL and not of the companies which have been covered in the Research Report. This report is intended for the sole use of the Recipient. Disclosures and analyst certifications are present in the Appendix.

**Anand Rathi Research India Equities** 

# **Quick Glance – Financials and Valuations (standalone)**

Fig 1 – Income statement (Rs m)											
Year-end: Mar	FY24	FY25	FY26e	FY27e	FY28e						
Net revenues	37,837	38,041	38,477	42,841	53,947						
Growth (%)	9.8	0.5	1.1	11.3	25.9						
Raw material	23,211	22,057	21,828	24,074	31,268						
Employee & other expenses	8,995	9,729	11,021	12,073	14,389						
EBITDA	5,631	6,255	5,628	6,694	8,290						
EBITDA margins (%)	14.9	16.4	14.6	15.6	15.4						
- Depreciation	1,095	1,227	1,285	1,421	1,594						
Other income	958	1,097	1,712	1,979	2,266						
Interest expenses	50	57	57	60	63						
PBT	5,444	6,068	5,998	7,192	8,899						
Effective tax rates (%)	26	24	25	25	25						
+ Associates / (Minorities)	-	-	-	-	-						
Adjusted income	4,048	4,587	4,499	5,394	6,674						
Extraordinary items	-	-	-	-	-						
Net income	4,048	4,587	4,499	5,394	6,674						
WANS	19	19	19	19	19						
FDEPS (Rs)	213.4	241.8	237.2	284.4	351.9						
Growth (%)	27.4	13.3	-1.9	19.9	23.7						

Year-end: Mar	FY24	FY25	FY26e	FY27e	FY28e
Share capital	95	95	95	95	95
Net worth	27,887	32,108	36,247	41,209	47,349
Debt	-	-	-	-	-
Minority interest	-	-	-	-	-
DTL / (Assets)	-290	-248	-254	-261	-270
Capital employed	27,597	31,860	35,993	40,948	47,080
Net tangible assets	6,538	7,093	7,275	7,632	8,872
Goodwill	-	-	-	-	-
CWIP (tang. & intang.)	825	633	666	888	1,554
Investments (strategic)	177	223	223	223	223
Investments (financial)	233	286	5,509	8,509	10,509
Current assets (excl. cash)	12,713	14,470	14,636	16,296	20,521
Cash	12,918	14,652	13,459	13,874	13,571
Current liabilities	5,807	5,497	5,775	6,473	8,170
Working capital	6,906	8,973	8,861	9,823	12,351
Capital deployed	27,597	31,860	35,993	40,948	47,080


Fig 3 - Cash-flow stat	ement (R	ls m)			
Year-end: Mar	FY24	FY25	FY26e	FY27e	FY28e
PBT	5,444	6,068	5,998	7,192	8,899
+ Non-cash items	232	312	1,342	1,481	1,657
Oper. prof. before WC	5,676	6,380	7,340	8,673	10,556
- Incr. / (decr.) in WC	1,971	2,283	-113	1,033	2,630
Others incl. taxes	1,778	1,361	1,505	1,805	2,234
Operating cash-flow	1,927	2,736	5,948	5,834	5,692
- Capex (tang. + intang.)	1,810	1,511	1,500	2,000	3,500
Free cash-flow	117	1,225	4,448	3,834	2,192
Acquisitions	-	-	-	-	-
- Div. (incl. taxes)	247	322	360	360	432
+ Equity raised / buyback	-	-	-	-	-
+ Debt raised	-	-	-	-	-
- Fin investments	-590	-29	5,223	3,000	2,000
- Misc. (CFI + CFF)	(770)	(802)	57	60	63
Net cash-flow	1,231	1,734	-1,193	414	-303
Source: Company, Anand Rathi F	Research				

V	EV04	EVOE	EVOC-	EV07-	EVO0-
Year-end: Mar	FY24	FY25	FY26e	FY27e	FY28e
P/E (x)	60.0	52.9	54.0	45.0	36.4
EV / EBITDA (x)	40.8	36.4	39.8	32.9	26.4
EV / Sales (x)	6.1	6.0	5.8	5.1	4.1
P/B (x)	8.7	7.6	6.7	5.9	5.1
RoE (%)	11.7	11.5	9.9	10.4	11.3
RoCE (%) - after tax	16.0	15.5	13.4	14.1	15.3
RoIC (%) - after tax	30.4	27.6	25.1	28.8	30.9
DPS (Rs)	17.0	19.0	19.0	22.8	28.1
Dividend yield (%)	0.1	0.1	0.1	0.2	0.2
Dividend payout (%)	8.0	7.9	8.0	8.0	8.0
Net debt / equity (x)	-0.5	-0.5	-0.5	-0.5	-0.5
Receivables (days)	90	107	107	107	107
Inventory (days)	16	18	18	18	18
Payables (days)	36	34	34	34	34
CFO: PAT (%)	48	60	132	108	85

## Fig 5 – Price movement



Fig 6 - Revenue mix (Q2 FY26 standalone)



# **Quarterly financials (standalone)**

Fig 7 – Quarterly performan	ice									
(Rs m)	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26	Y/Y (%)	Q/Q (%)	YTD FY26	YTD FY25	Y/Y (%)
Revenue	9,067	9,559	10,032	9,632	9,018	(0.5)	(6.4)	18,650	18,450	1.1
Expenditure	7,672	7,806	8,307	8,353	7,697	0.3	(7.9)	16,050	15,674	2.4
as % of sales	84.6	81.7	82.8	86.7	85.3			86.1	85.0	
Consumption of RM	5,239	5,420	5,841	5,574	5,078	(3.1)	(8.9)	10,651	10,796	(1.3)
as % of sales	57.8	56.7	58.2	57.9	56.3			57.1	58.5	
Employee cost	1,328	1,402	1,292	1,501	1,440	8.4	(4.0)	2,941	2,691	9.3
as % of sales	14.7	14.7	12.9	15.6	16.0			15.8	14.6	
Other expenditure	1,105	983	1,173	1,279	1,179	6.7	(7.8)	2,458	2,187	12.4
as % of sales	12.2	10.3	11.7	13.3	13.1			13.2	11.9	
EBITDA	1,395	1,753	1,725	1,279	1,321	(5.3)	3.3	2,601	2,777	(6.3)
EBITDA margins (%)	15.4	18.3	17.2	13.3	14.7			13.9	15.0	
Depreciation	311	314	315	322	317	2.0	(1.5)	639	598	6.9
EBIT	1,084	1,439	1,410	957	1,004	(7.4)	4.9	1,962	2,179	(10.0)
Other income	397	172	274	671	445	12.3	(33.6)	1,116	652	71.2
Interest	13	12	14	13	12	(4.0)	(5.2)	26	31	(16.6)
PBT	1,467	1,598	1,670	1,615	1,437	(2.1)	(11.0)	3,052	2,800	9.0
Total tax	374	349	418	413	372	(0.5)	(9.9)	785	715	9.9
Adj. PAT	1,093	1,249	1,252	1,202	1,065	(2.6)	(11.4)	2,266	2,086	8.7
Extra ordinary items (loss) / gain	-	-	-	-	-			-	-	
Reported PAT	1,093	1,249	1,252	1,202	1,065	(2.6)	(11.4)	2,266	2,086	8.7
Adj. EPS (Rs)	57.6	65.9	66.0	63.4	56.1	(2.6)	(11.4)	119.5	110.0	8.7
Margins (%)						(bps)	(bps)			(bps)
Gross	42.2	43.3	41.8	42.1	43.7	147	156	42.9	41.5	140
EBIDTA	15.4	18.3	17.2	13.3	14.7	(73)	137	13.9	15.0	(110)
EBIT	12.0	15.1	14.1	9.9	11.1	(82)	120	10.5	11.8	(129)
PAT	12.1	13.1	12.5	12.5	11.8	(25)	(67)	12.2	11.3	85
Effective tax rates	25.5	21.8	25.0	25.6	25.9	42	33	25.7	25.5	21
Source: Compa										

_		Old			Revised		Change (%)		
(Rs m)	FY26e	FY27e	FY28e	FY26e	FY27e	FY28e	FY26	FY27	FY28
Revenue	39,336	44,330	53,868	38,477	42,841	53,947	-2.2	-3.4	0.1
EBITDA	6,154	7,096	8,558	5,628	6,694	8,290	-8.5	-5.7	-3.1
% of revenue	15.6%	16.0%	15.9%	14.6%	15.6%	15.4%			
Adj. PAT	4,365	5,386	6,496	4,499	5,394	6,674	3.1	0.1	2.7
EPS (Rs)	230.1	284.0	342.5	237.2	284.4	351.9	3.1	0.1	2.7

# **Earnings call takeaways**

- **OEM** (consolidated) sales grew 7.4% y/y, broadly in line with production (CV >6 tonnes up 7.6%), despite adverse tonnage mix, owing to higher ESC penetration (Sep'25 regulation) and market-share gains in e-compressors (EV applications). Only local supplier for e-compressors (some OEMs are importing a little). Focusing on deeper penetration of trailer ABS, trailer EBS, scalar EVO telematics, exhaust brake valve, AMT, ECAS and EV buses (e-compressor, EBS, ESC, ECAS) products. EBS gives regen capability and sees demand with EVs. Disc-brake penetration also goes in tandem with EBS but due to cost, adoption is low. AMT penetration is low at few hundred volumes/month, though penetration is increasing for mining (higher powered engines) trucks and city buses.
- **ESC.** Updated regulation has been effective from Sep'25. Pneumatic volumes up 40-45% y/y. Hydraulic volumes slightly up (caters to LCVs), awaiting regulation for school buses (in a draft stage), which would lift volumes. Working on localisation to sustain market share.
- **ADAS regulation.** Delay expected, while exact dates may be out in a few months.
- Aftermarket sales grew 12.6% y/y. Driven by retro-fitment of trailer ABS/ESC (petro companies), DCS, clutch boosters and OES (BS4/6 models replacement demand).
- Export products fell 16% y/y. US down ~20% due to tariffs, partially offset by growth in Europe (up 9%) and EMEA. Air compressor (BMW) demand soft. Started supply of actuator 4.0 and air-compressors to other global OEMs. Smart actuators (an upgrade to current actuators) are being planned for Europe.
- Export services grew 12.1% y/y.
- Manufacturing update. Rollout of brake signal transmitter for e-mobility applications and supplying leading India OEMs. Expanded further with relay walls, high force actuators and localised ASP cartridges for both OEM and aftermarket. Assembly lines at Lucknow and Pantnagar have been upgraded.
- **Management changes.** Andreas Moser appointed Board member of CV solutions for the India region in place of Peter Laier.

## **Valuation**

More content because of regulations, EVs. The ADAS regulation draft notification is out, proposing ESC (Rs25,000), AEBS and four ADAS functions (>Rs40,000), with content opportunity of over Rs65,000 per CV (>9-tonne trucks/buses). ESC regulation for most bus segments is implemented from Sep'25. Electric vehicles and trailer penetration would drive products such as electric compressors (Rs80,000), EBS (Rs60,000) and trailer ABS (Rs30,000). Content, due to government regulations, would increase in stages for CVs on penetration of ESC, AEBS, ADAS and EVs, with potential to more than double ahead. The dominant market share is expected to continue across M&H CVs.

Analysis of impact of ADAS regulations. Of Rs65,000 CPV, assuming implementation in phases with content of Rs32,500 from Oct'27 and Rs32,500 from Oct'28, revenue would record a 17% CAGR (OEM at 25%) over FY25-30 and a 25% CAGR (OEM at 37%) over FY27-30.

**Exports** to be driven by market-share gains in CVs/PVs from group companies. The wider distribution network and retro-fitment solutions would drive the **aftermarket**. **Service** revenue would increase, led by more software sales and R&D support to group companies.

**LCV segment expansion** would see products such as hydraulic ABS, vacuum-brake boosters, vacuum pumps, ADAS and lightweight calipers. The portfolio targets more EVs (for models like Tata's ACE). €90m revenue targeted by 2030, with double-digit margins in the long run. Portfolio expansion has been driven by levering ZF's global products.

**Better M&H CV** demand ahead. India's M&H CV sector is likely to see a 5% CAGR over FY25-28. The overseas CV sector could be muted in the near term, but export revenue would outstrip that of the industry due to sourcing by global group companies.

**View, Valuation.** We expect a 12% revenue CAGR over FY25-28, led by 18% in OEMs, 9% in aftermarket, 5% in exports and 12% in services. We expect 10/13% EBITDA/PAT CAGRs over FY25-28. We recommend a Buy at a TP of Rs15,900, 50x Sep'27e P/E.

Fig 9 – Key assumptions							
Segmental revenue (Rs m)	FY25	FY26e	FY27e	FY28e	FY29e	FY30e	CAGR FY25-30 (%)
OEMs	16,427	17,283	19,472	27,064	40,131	49,710	25
Y/Y change, %	-10	5	13	39	48	24	
Exports	11,647	10,133	11,146	13,375	15,382	17,612	9
Y/Y change, %	8	-13	10	20	15	15	
Aftermarket	5,054	5,559	6,060	6,605	7,200	7,848	9
Y/Y change, %	6	10	9	9	9	9	
Other operating income / Service	4,913	5,502	6,163	6,902	7,661	8,428	11
Y/Y change, %	20	12	12	12	11	10	
Revenues	38,041	38,477	42,841	53,947	70,374	83,597	17
Y/Y change, %	1	1	11	26	30	19	
Source: Company, Anand Rathi Research							

120
110
100
90
80
70
60
50
40
30
20
91-NeW
Web-22
Nov-23
Nov-23
Nov-23
Nov-23
Nov-23
Nov-23
Nov-23
Nov-24
Nov-25
Nov-25
Nov-26
Nov-27
Nov-27
Nov-28
Nov-28
Nov-29
N

Fig 10 – Valuation chart (1yr-forward P/E) – Historical median is 55x

## Source: Bloomberg, Anand Rathi Research

## Downside risks


- Less-than-expected growth in underlying segments.
- Delay in new regulations for CVs.
- Adverse commodities/forex movement.
- Trade wars

## **Appendix**

### **Analyst Certification**

The views expressed in this Research Report accurately reflect the personal views of the analyst(s) about the subject securities or issuers and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this report. The research analysts are bound by stringent internal regulations and also legal and statutory requirements of the Securities and Exchange Board of India (hereinafter "SEBI") and the analysts' compensation are completely delinked from all the other companies and/or entities of Anand Rathi, and have no bearing whatsoever on any recommendation that they have given in the Research Report.

Important Disclosures on subject companies Rating and Target Price History (as of 6 November 2025)



### Anand Rathi Ratings Definitions

Analysts' ratings and the corresponding expected returns take into account our definitions of Large Caps, Mid Caps & Small Caps as described in the Ratings Table below:

Ratings Guide (12 months)				
	Buy	Hold	Sell	
Large Caps (Top 100 companies)	>15%	0-15%	<0%	
Mid Caps (101st-250th company)	>20%	0-20%	<0%	
Small Caps (251st company onwards)	>25%	0-25%	<0%	

## Research Disclaimer and Disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014

Anand Rathi Share and Stock Brokers Ltd. (hereinafter refer as ARSSBL) (Research Entity, SEBI Regn No. INH000000834, Date of Regn. 29/06/2015, BSE Enlistment Number – 5048 date of Regn 25 July 2024) is a subsidiary of the Anand Rathi Financial Services Ltd. ARSSBL is a corporate trading and clearing member of Bombay Stock Exchange Ltd (BSE), National Stock Exchange of India Ltd. (NSEIL),Multi Commodity Exchange of India Limited (MCX),National Commodity & Derivatives Exchange Limited (NCDEX), and also depository participant with National Securities Depository Ltd (NSDL) and Central Depository Services Ltd. (CDSL), ARSSBL is engaged into the business of Stock Broking, Depository Participant, Mutual Fund distributor.

The research analysts, strategists, or research associates principally responsible for the preparation of Anand Rathi research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors and firm revenues.

General Disclaimer: This Research Report (hereinafter called "Report") is meant solely for use by the recipient and is not for circulation. This Report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, derivatives or any other security through ARSSBL nor any solicitation or offering of any investment /trading opportunity on behalf of the issuer(s) of the respective security (ies) referred to herein. These information / opinions / views are not meant to serve as a professional investment guide for the readers. No action is solicited based upon the information provided herein. Recipients of this Report should rely on information/data arising out of their own investigations. Readers are advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments. This Report has been prepared on the basis of publicly available information, internally developed data and other sources believed by ARSSBL to be reliable. ARSSBL or its directors, employees, affiliates or representatives do not assume any responsibility for, or warrant the accuracy, completeness, adequacy and reliability of such information / opinions / views. While due care has been taken to ensure that the disclosures and opinions given are fair and reasonable, none of the directors, employees, affiliates or representatives of ARSSBL shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatsoever from the information / opinions / views contained in this Report. The price and value of the investments referred to in this Report and the income from them may go down as well as up, and

Opinions expressed are our current opinions as of the date appearing on this Research only. We do not undertake to advise you as to any change of our views expressed in this Report. Research Report may differ between ARSSBL's RAs and/ or ARSSBL's associate companies on account of differences in research methodology, personal judgment and difference in time horizons for which recommendations are made. User should keep this risk in mind and not hold ARSSBL, its employees and associates responsible for any losses, damages of any type whatsoever.

ARSSBL and its associates or employees may; (a) from time to time, have long or short positions in, and buy or sell the investments in/ security of company (ies) mentioned herein or (b) be engaged in any other transaction involving such investments/ securities of company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) these and other activities of ARSSBL and its associates or employees may not be construed as potential conflict of interest with respect to any recommendation and related information and opinions. Without limiting any of the foregoing, in no event shall ARSSBL and its associates or employees or any third party involved in, or related to computing or compiling the information have any liability for any damages of any kind.

Details of Associates of ARSSBL and Brief History of Disciplinary action by regulatory authorities & its associates are available on our website i.e. www.rathionline.com

Disclaimers in respect of jurisdiction: This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject ARSSBL to any registration or licensing requirement within such jurisdiction(s). No action has been or will be taken by ARSSBL in any jurisdiction (other than India), where any action for such purpose(s) is required. Accordingly, this Report shall not be possessed, circulated and/or distributed in any such country or jurisdiction unless such action is in compliance with all applicable laws and regulations of such country or jurisdiction. ARSSBL requires such recipient to inform himself about and to observe any restrictions at his own expense, without any liability to ARSSBL. Any dispute arising out of this Report shall be subject to the exclusive jurisdiction of the Courts in India.

Statements on ownership and material conflicts of interest, compensation - ARSSBL and Associates

#### Answers to the Best of the knowledge and belief of ARSSBL/ its Associates/ Research Analyst who is preparing this report

Research analyst or research entity or his associate or his relative has any financial interest in the subject company and the nature of such financial interest.	No	
ARSSBL/its Associates/ Research Analyst/ his Relative have actual/beneficial ownership of one per cent or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report?	No	
ARSSBL/its Associates/ Research Analyst/ his Relative have actual/beneficial ownership of one per cent or more securities of the subject company	No	
ARSSBL/its Associates/ Research Analyst/ his Relative have any other material conflict of interest at the time of publication of the research report?	No	
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation from the subject company in the past twelve months	No	
ARSSBL/its Associates/ Research Analyst/ his Relative have managed or co-managed public offering of securities for the subject company in the past twelve months	No	
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No	
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No	
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation or other benefits from the subject company or third party in connection with the research report	No	
ARSSBL/its Associates/ Research Analyst/ his Relative have served as an officer, director or employee of the subject company.	No	
ARSSBL/its Associates/ Research Analyst/ his Relative has been engaged in market making activity for the subject company.	No	

### NOTICE TO US INVESTORS:

This research report is the product of Anand Rathi Share and Stock Brokers Limited, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated person(s) of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances, and trading securities held by a research analyst account.

Research reports are intended for distribution only to Major U.S. Institutional Investors as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act of 1934 (the Exchange Act) and interpretations thereof by the U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a-6(a)(2). If the recipient of this research report is not a Major U.S. Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated, and/or transmitted onward to any U.S. person which is not a Major U.S. Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major U.S. Institutional Investors, Anand Rathi Share and Stock Brokers Limited has entered into a Strategic Partnership and chaperoning agreement with a U.S. registered broker-dealer: Banc Trust Securities USA. Transactions in securities discussed in this research report should be affected through Banc Trust Securities USA.

- 1. ARSSBL or its Affiliates may or may not have been beneficial owners of the securities mentioned in this report.
- 2. ARSSBL or its affiliates may have or not managed or co-managed a public offering of the securities mentioned in the report in the past 12 months.
- 3. ARSSBL or its affiliates may have or not received compensation for investment banking services from the issuer of these securities in the past 12 months and do not expect to receive compensation for investment banking services from the issuer of these securities within the next three months.
- 4. However, one or more of ARSSBL or its Affiliates may, from time to time, have a long or short position in any of the securities mentioned herein and may buy or sell those securities or options thereon, either on their own account or on behalf of their clients.
- 5. As of the publication of this report, ARSSBL does not make a market in the subject securities.
- 6. ARSSBL or its Affiliates may or may not, to the extent permitted by law, act upon or use the above material or the conclusions stated above, or the research or analysis on which they are based before the material is published to recipients and from time to time, provide investment banking, investment management or other services for or solicit to seek to obtain investment banking, or other securities business from, any entity referred to in this report.
- © 2025. This report is strictly confidential and is being furnished to you solely for your information. All material presented in this report, unless specifically indicated otherwise, is under copyright to ARSSBL. None of the material, its content, or any copy of such material or content, may be altered in any way, transmitted, copied or reproduced (in whole or in part) or redistributed in any form to any other party, without the prior express written permission of ARSSBL. All trademarks, service marks and logos used in this report are trademarks or service marks or registered trademarks or service marks or ser

As of the publication of this report, ARSSBL does not make a market in the subject securities.

Registration granted by SEBI, Enlistment as RA and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Additional information on recommended securities/instruments is available on request.

Compliance officer: Deepak Kedia, email id: deepakkedia@rathi.com, Contact no. +91 22 6281 7000
Grievance officer: Madhu Jain, email id: grievance@rathi.com, Contact no. +91 22 6281 7191

ARSSBL registered address: Express Zone, A Wing, 10th Floor, Western Express Highway, Diagonally Opposite Oberoi Mall, Malad (E), Mumbai – 400097.

Tel No: +91 22 6281 7000 | Fax No: +91 22 4001 3770 | CIN: U67120MH1991PLC064106.